Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies Inc (ALUR) delivers innovative weight management solutions through its swallowable gastric balloon and integrated digital platform. This page provides authorized updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of non-invasive obesity treatment.
Investors and healthcare professionals will find timely announcements including quarterly earnings reports, FDA regulatory updates, partnerships with medical institutions, and new clinical study findings. Our curated news collection ensures transparent access to material events affecting the company's position in the medical device sector.
Key content categories include product innovation timelines, peer-reviewed research publications, executive leadership changes, and global expansion updates. Each announcement is sourced directly from official corporate communications to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Allurion's latest developments in AI-powered patient monitoring systems and procedure-less weight loss technologies. Regularly updated to reflect the company's progress in merging medical devices with digital health solutions.
Allurion Technologies (NYSE: ALUR) announced three presentations at the European Congress on Obesity (ECO) held from May 12-15, 2024, in Venice, Italy. The presentations highlighted data from a study involving 712 patients across six obesity centers, demonstrating an average total body weight loss (TBWL) of 14.1% in four months, with 70% of the weight loss from fat mass and only 30% from lean body mass. The Allurion Program, which includes the Allurion Balloon and Virtual Care Suite, aims to preserve lean body mass during weight loss. Additionally, previous studies showed that more intensive programs led to 100% fat mass-derived weight loss without muscle mass loss. The presentations also covered behavior change coaching and the positive impact of GLP-1s on the program.
Allurion Technologies (NYSE: ALUR) announced its Q1 2024 financial results with a revenue of $9.4 million, a 14% increase from Q4 2023 but a decrease from $14.1 million in Q1 2023. Procedural volume rose 12% year-over-year and 22% sequentially. Cash burn decreased to $8.4 million from $22 million in Q4 2023. Notable developments include treating the first NHS patient with the Allurion Balloon, launching the VCS digital platform in the U.S., and securing $48 million in financing. Operating expenses were reduced significantly, but a year-over-year revenue decline and lower gross profit margins were noted.
Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.
Allurion Technologies, Inc. announced preliminary first quarter 2024 results, with quarter-over-quarter revenue growth, procedural volume growth, and a significant decrease in cash burn. The company expects revenue between $9.2 million to $9.3 million, 12%-13% higher than the fourth quarter of 2023, procedural volume growth of 22%, and reduced cash burn of $8 million to $9 million. Allurion remains optimistic about future growth and business opportunities.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
